Tirzepatide 60mg
Dual GIP and GLP-1 receptor agonist studied for body weight management, insulin sensitivity, and metabolic regulation.
Mechanism
Co-activates GIP and GLP-1 incretin receptors to enhance glucose-dependent insulin secretion, slow gastrointestinal motility, and downregulate central appetite pathways.
Dosing
Standard research protocols initiate investigation at a conservative baseline dose of 2.5 mg administered subcutaneously once weekly.
Reconstitution
Reconstituting a 60 mg vial with 3.0 mL of bacteriostatic water yields a peptide concentration of 20 mg/mL.
Storage
Store the unmixed lyophilized powder frozen at -20°C shielded from light, and keep the reconstituted solution refrigerated at 2–8°C for up to 4 weeks.
Mix & measure Tirzepatide 60mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Tirzepatide 60mg
Vial strength → BAC water → target dose
Total doses in vial: 24.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg once weekly | 12.5 units (0.125 mL) |
| Weeks 5–8 | 5 mg once weekly | 25 units (0.25 mL) |
| Weeks 9–12 | 7.5 mg once weekly | 37.5 units (0.375 mL) |
| Weeks 13–16 | 10 mg once weekly | 50 units (0.50 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Introduce the bacteriostatic water slowly down the interior glass wall of the 60 mg vial to limit foaming.
- 3
Gently roll or swirl the vial until the lyophilized cake is fully dissolved without vigorous agitation.
- 4
Record the date of preparation on the vial and refrigerate immediately between 2–8°C away from light.
Supplies Needed
Peptide Vial
Contains 60 mg of lyophilized Tirzepatide research compound.
Insulin Syringes (U-100)
Used for precise measurement and subcutaneous administration of research doses.
Bacteriostatic Water
Serves as the sterile, preserved diluent to reconstitute the peptide cake.
Alcohol Swabs
Utilized to sanitize the rubber vial stopper and clean the experimental administration site.
Why researchers study it
Weight management and adiposity reduction
Glycemic control and HbA1c moderation
Appetite suppression and gastric motility dynamics
Cardiometabolic markers and lipid modulation
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Tirzepatide is a synthetic dual incretin mimetic designed to target both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By engaging both pathways synergistically, it influences systemic energy balance, enhances insulin secretion in response to glucose, diminishes inappropriate glucagon release, and reduces overall caloric consumption via delayed gastric transit and centrally mediated satiety signaling. In extensive clinical investigations, including the SURMOUNT and SURPASS trial programs, the peptide demonstrated pronounced dose-dependent reductions in total body mass alongside improvements in glycemic control and cardiovascular risk parameters. Its chemical structure confers an extended terminal elimination half-life of approximately five to six days, enabling once-weekly subcutaneous dosing schedules in experimental models. Investigational titration protocols emphasize a gradual stepwise increment in weekly dosing to mitigate gastrointestinal side effects such as nausea or dyspepsia. Research-grade preparations packaged in high-capacity 60 mg vials offer flexible volume scaling across prolonged longitudinal studies requiring progressive dosage increases.
References
- 1.Jastreboff et al., New England Journal of Medicine, 2022 — SURMOUNT-1 trial evaluating tirzepatide for obesity management
- 2.SURMOUNT Program Investigators, New England Journal of Medicine, 2023 — Once-weekly tirzepatide 72-week weight outcomes
- 3.JAMA Network Authors, JAMA, 2023 — Tirzepatide efficacy and safety profiles across obesity trials
- 4.The Lancet Investigators, The Lancet, 2023 — Glycemic and weight outcomes of tirzepatide in type 2 diabetes
- 5.Review Authors, Metabolites, 2025 — Mechanism of action and clinical landscape of dual GIP/GLP-1 receptor agonism
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.